CA2525615C - Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine - Google Patents
Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine Download PDFInfo
- Publication number
- CA2525615C CA2525615C CA2525615A CA2525615A CA2525615C CA 2525615 C CA2525615 C CA 2525615C CA 2525615 A CA2525615 A CA 2525615A CA 2525615 A CA2525615 A CA 2525615A CA 2525615 C CA2525615 C CA 2525615C
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- iron
- iron phosphate
- vaccine composition
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to vaccination compositions comprising iron phosphate as a pharmaceutical aid. Said iron phosphate is present in the form of particles whose size ranges from 0.01~m and 300~m; it can be obtained by mixing an iron salt and phosphate salt solution.
Description
Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine The present invention relates to the vaccines field, and in particular to the field of vaccine compositions comprising an adjuvant. More particularly, the present invention relates to a vaccine in which the adjuvant comprises iron phosphate.
Vaccine compositions comprising adjuvants intended to increase or to qualitatively modify the immune response induced when an antigen is administered are known in the prior art. In fact, the developments realized in the vaccine industry result in the use of antigens obtained from viruses or from bacteria, but with increasingly developed purification methods, and also of antigens derived from biotechnology. These antigens have the advantage of generally being purer than some of the antigens used in the past, but, in return, they are often less immunogenic and therefore require the use of an adjuvant.
Many adjuvants have already been described: saponins, emulsions, cationic lipids, etc.
However, to date, the only adjuvants commonly used in the marketed products are aluminum-based adjuvants.
Now, it would be desirable to have other adjuvants.
Among the prior art relating to adjuvants, mention may in particular be made of US patent 5,895,653, which describes, as adjuvant, iron hydroxide compounds in the form of a colloidal solution, the adsorbent capacity of which is thought to be improved compared to the iron hydroxides previously described in the form of a gel.
However, such adjuvants, while they present an alternative to the aluminum-based adjuvants currently used, cannot always effectively replace them, and it is therefore desirable to have other compounds, the characteristics of which are such that at the same time they exhibit good tolerance with respect to the organisms to which they are administered, they can be produced under conditions compatible with the constraints of the pharmaceutical industry and, especially, they make it possible to increase or to modify the immune response to vaccine antigens in a manner which is at least as effective as the aluminum-based compounds currently used.
With this aim, the subject of the present invention is a vaccine composition comprising at least one vaccine antigen and at least one adjuvant, characterized in that the adjuvant comprises iron phosphate.
According to a particular characteristic, the iron phosphate is present in the form of a suspension of particles, the size of which is between 0.01 pm and 300 pm, and more particularly between 1 and 40 pm, with in particular a large proportion of particles, the size of which is approximately 7 pm.
According to a particular embodiment of the present invention, the iron phosphate is prepared from a solution of iron salt and of phosphate salt.
Such a preparation makes it possible to obtain a whitish non-crystalline product providing all the safety conditions required for administration to humans, generally in good health.
Vaccine compositions comprising adjuvants intended to increase or to qualitatively modify the immune response induced when an antigen is administered are known in the prior art. In fact, the developments realized in the vaccine industry result in the use of antigens obtained from viruses or from bacteria, but with increasingly developed purification methods, and also of antigens derived from biotechnology. These antigens have the advantage of generally being purer than some of the antigens used in the past, but, in return, they are often less immunogenic and therefore require the use of an adjuvant.
Many adjuvants have already been described: saponins, emulsions, cationic lipids, etc.
However, to date, the only adjuvants commonly used in the marketed products are aluminum-based adjuvants.
Now, it would be desirable to have other adjuvants.
Among the prior art relating to adjuvants, mention may in particular be made of US patent 5,895,653, which describes, as adjuvant, iron hydroxide compounds in the form of a colloidal solution, the adsorbent capacity of which is thought to be improved compared to the iron hydroxides previously described in the form of a gel.
However, such adjuvants, while they present an alternative to the aluminum-based adjuvants currently used, cannot always effectively replace them, and it is therefore desirable to have other compounds, the characteristics of which are such that at the same time they exhibit good tolerance with respect to the organisms to which they are administered, they can be produced under conditions compatible with the constraints of the pharmaceutical industry and, especially, they make it possible to increase or to modify the immune response to vaccine antigens in a manner which is at least as effective as the aluminum-based compounds currently used.
With this aim, the subject of the present invention is a vaccine composition comprising at least one vaccine antigen and at least one adjuvant, characterized in that the adjuvant comprises iron phosphate.
According to a particular characteristic, the iron phosphate is present in the form of a suspension of particles, the size of which is between 0.01 pm and 300 pm, and more particularly between 1 and 40 pm, with in particular a large proportion of particles, the size of which is approximately 7 pm.
According to a particular embodiment of the present invention, the iron phosphate is prepared from a solution of iron salt and of phosphate salt.
Such a preparation makes it possible to obtain a whitish non-crystalline product providing all the safety conditions required for administration to humans, generally in good health.
Many advantages of the present invention will emerge in the course of the description which will follow with reference to the figures which illustrate results obtained in the tests described in example 3.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 represents the IgG1 results after a 1st immunization.
Figure 2 represents the IgG1 results obtained after the 2nd immunization.
Figure 3 represents the IgG2a results obtained after the 1 st immunization.
Figure 4 represents the IgG2a results obtained after the 2nd immunization.
For the purpose of the present invention, the term "vaccine composition" is intended to mean a composition which can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in a production of antibodies or simply in the activation of certain cells, in particular antigen-presenting cells, T lymphocytes and B lymphocytes. The vaccine composition can be a composition for prophylactic purposes or for therapeutic purposes, or both.
For the purpose of the present invention, the term "antigen" is intended to mean any antigen which can be used in a vaccine, whether it involves a whole micro-organism or a subunit, and whatever its nature:
peptide, protein, glycoprotein, polysaccharide, glyco-lipid, lipopeptide, etc. They may be viral antigens, bacterial antigens, or the like; the term "antigen"
also comprises the polynucleotides, the sequences of 3a which are chosen so as to encode the antigens whose expression by the individuals to which the polynucleotides are administered is desired, in the case of the immunization technique referred to as DNA
immunization. They may also be a set of antigens, in particular in the case of a multivalent vaccine composition which comprises antigens capable of protecting against several diseases, and which is then generally referred to as a vaccine combination, or in the case of a composition which comprises several different antigens in order to protect against a single disease, as is the case for certain vaccines against whooping cough or the flu, for example.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 represents the IgG1 results after a 1st immunization.
Figure 2 represents the IgG1 results obtained after the 2nd immunization.
Figure 3 represents the IgG2a results obtained after the 1 st immunization.
Figure 4 represents the IgG2a results obtained after the 2nd immunization.
For the purpose of the present invention, the term "vaccine composition" is intended to mean a composition which can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in a production of antibodies or simply in the activation of certain cells, in particular antigen-presenting cells, T lymphocytes and B lymphocytes. The vaccine composition can be a composition for prophylactic purposes or for therapeutic purposes, or both.
For the purpose of the present invention, the term "antigen" is intended to mean any antigen which can be used in a vaccine, whether it involves a whole micro-organism or a subunit, and whatever its nature:
peptide, protein, glycoprotein, polysaccharide, glyco-lipid, lipopeptide, etc. They may be viral antigens, bacterial antigens, or the like; the term "antigen"
also comprises the polynucleotides, the sequences of 3a which are chosen so as to encode the antigens whose expression by the individuals to which the polynucleotides are administered is desired, in the case of the immunization technique referred to as DNA
immunization. They may also be a set of antigens, in particular in the case of a multivalent vaccine composition which comprises antigens capable of protecting against several diseases, and which is then generally referred to as a vaccine combination, or in the case of a composition which comprises several different antigens in order to protect against a single disease, as is the case for certain vaccines against whooping cough or the flu, for example.
Particularly good results have in particular been obtained with a vaccine composition comprising antigens against diphtheria, tetanus and poliomyelitis.
For the purposes of the present invention, the iron phosphate is an inert mineral compound based on amorphous, crystalline or pseudocrystalline iron phosphate. Very satisfactory tests have been achieved with an amorphous iron phosphate.
Such a compound is prepared from a solution of iron salt and of phosphate salt.
As iron salt, mention may in particular be made of iron citrate or, particularly advantageously, iron chloride.
As phosphate salt, use may in particular be made of sodium phosphate.
The iron phosphate can be prepared by simultaneously or successively mixing the two starting components. The order of the mixing can be either the addition of iron chloride to sodium phosphate or, conversely, the addition of sodium phosphate to iron chloride. The rate of addition can be very rapid or, on the contrary, dropwise.
To obtain an iron phosphate suitable for the needs of the invention, it has been noted that a ratio of 2 times more iron salt than phosphate salt is satisfactory.
Alternatively, the iron phosphate can be prepared using a nebulizer. In this case, the sodium phosphate can be nebulized in a solution of iron chloride or, conversely, the iron chloride in the sodium phosphate.
During the preparation of the vaccine compositions -according to the invention, the iron phosphate can be introduced into the vaccine composition at the very beginning of the formulation. The iron phosphate is then diluted to a certain concentration, and the 5 antigens of interest are then added thereto.
Alternatively, it is possible to add the iron phosphate to a lyophilisate already comprising the portion of the vaccine composition which contains the antigens of interest.
According to the invention, the iron phosphate is present in the vaccine composition in a sufficient amount to exert an adjuvant action.
When it is the only adjuvant used, the dose of vaccine composition administered can comprise between 0.2 and 1.4 mg of iron phosphate.
When it is combined with another adjuvant, the amounts present can be reduced, as a function of the desired adjuvant effect and of the potency of the other adjuvants present.
Local and systemic toxicity tests on rabbits have shown that iron phosphate is as well tolerated as aluminum hydroxide.
The following examples illustrate particular embodiments of the present invention.
Example 1: Preparation of iron phosphate and of iron hydroxide The iron phosphate is prepared by mixing FeC13.6H20 at 0.5 M (supplied by SIGMA under the batch reference 55H 1251) in a solution of Na2HPO4.2H2O at 0.25 M
(supplied by Merck with the batch reference FA004911).
= - 6 -The 2 products are mixed in the following proportions:
1 1 of ultrafiltered water comprising 44.5 g of Na2HPO4.2H20 is combined with a solution of 800 ml of ultrafiltered H2O comprising 108.12 g of FeC13.6H20. The mixing is performed at ambient temperature.
Stirring is performed for 15 minutes by means of a rod-stirrer and then successive centrifugations are carried out with the precipitate being washed with water. After each wash, the presence of chloride ions is detected by assaying the chloride ions with silver nitrate. When there are no longer any chloride ions, i.e. after 10 washes, the precipitate is taken up in water and autoclaved for 1 h at 118 C in order to ensure its sterility.
The solution obtained in this manner is an iron phosphate solution containing 16 g Fe/1.
The iron hydroxide is prepared by mixing 0.5 M iron citrate and 2 M NaOH, at ambient temperature. NaOH is added dropwise to 100 ml of iron citrate until a pH of 8 is obtained. In the same way as for the preparation of the iron phosphate, stirring is performed for 15 minutes and then successive centrifugations are carried out with the precipitate being washed with water, and the chloride ions being assayed with silver nitrate. When chloride ions are no longer detected, the precipitate is taken up in water and autoclaved for 1 h at 118 C in order to be sterile. The solution then obtained is an iron hydroxide solution containing 6.3 g Fe/l.
Example 2: Preparation of the vaccine compositions Using the solutions prepared as indicated above, an aqueous suspension of aluminum hydroxide (supplied by Reheis) comprising 10.8 g of Al/l, and also a preparation of PTP (purified tetanus protein) at a concentration of 330 flocculation or Lf units/ml (i.e.
a protein concentration of 0.9125 g/1), the following compositions are prepared:
= PTP alone: 840 pl H2O + 120 pl 9% NaC1 +
240 PTP at 100 Lf/ml, = PTP and A1OOH : 618 pl H2O + 222 pl A100H at 10.8 g of Al/l + 120 pl 9% NaC1 + 240 PTP at 100 Lf/ml, = PTP and FePO4: 690 pl H2O + 150 pl. FePO4 at 16 g/l + 120 p1 of a 10 times-concentrated PBS
buffer solution (i.e. 95 mM Na2HPO4.2H2O) +
240 PTP at 100 Lf/ml, = PTP and FeOOH: 458 pl H2O + 382 pl FeOOH at 6.3 g of Fe/1 + 120 p1 of a 10 times-concentrated PBS buffer solution + 240 PTP at 100 Lf/ml.
Example 3: Assaying of the anti-tetanus antibodies 4 groups of six 6-week-old female OF1 mice are used.
One of the formulations prepared in example 2 is administered to each group of mice. The administration is performed intramuscularly in the quadriceps under anesthesia, at a rate of 2 injections of 50 pl on days Dl and D22. The amount administered is therefore 2 flocculation or Lf units of PTP and 0.2 mg of mineral material (either aluminum or iron) in the case of the formulations comprising an adjuvant.
On D15, a blood sample of approximately 300 pl is taken from the retro-orbital sinus in each mouse.
On D36, the mice are bled out under anesthesia, by sectioning of the carotid.
The PTP-specific IgGls and IgG2as are assayed, by the ELISA method, on each of the sera corresponding to the bloods collected.
The results obtained are given in figures 1 to 4 and show that the iron phosphate is a good adjuvant; as regards the IgGis, the results obtained are clearly superior to those obtained when the antigen is administered alone, even though they are not quite as good as those obtained with the aluminum hydroxide; as regards the IgG2as, the titers obtained are as high as those obtained with the aluminum hydroxide.
Example 4: Verification of the anti-tetanus activity The anti-tetanus activity of the compositions according to the invention is verified by means of a test consisting in evaluating, in mice, the activity of these compounds with respect to a lethal dose of toxin administered subcutaneously.
The activity of the compositions tested is determined by comparing the dose required to protect 50% of the animals (ED50) against the effects of the toxin, with that of a reference vaccine calibrated in IU/ml.
The formulations tested are obtained by mixing the adjuvant (0.6 mg/dose) with water, 30 Lf of PDT
(diphtheria toxoid) and 10 Lf of PTT (tetanus toxoid), and then adding 20 pg/dose of merthiolate and a saline solution (solution containing 90 g/l of NaC1 and 5 mM
Na2HP04.2H20) .
The vaccine compositions tested comprise either aluminum hydroxide or iron phosphate or iron hydroxide.
The results obtained with each of the adjuvants tested are reported in the table below, and show that iron phosphate is a good adjuvant, clearly better than iron hydroxide under the same conditions:
Adjuvants Tetanus activity (IU/dose) A100H 103 (76-139) FePO4 32 (24-43) FeOOH 8.2 (5.4-12.5)
For the purposes of the present invention, the iron phosphate is an inert mineral compound based on amorphous, crystalline or pseudocrystalline iron phosphate. Very satisfactory tests have been achieved with an amorphous iron phosphate.
Such a compound is prepared from a solution of iron salt and of phosphate salt.
As iron salt, mention may in particular be made of iron citrate or, particularly advantageously, iron chloride.
As phosphate salt, use may in particular be made of sodium phosphate.
The iron phosphate can be prepared by simultaneously or successively mixing the two starting components. The order of the mixing can be either the addition of iron chloride to sodium phosphate or, conversely, the addition of sodium phosphate to iron chloride. The rate of addition can be very rapid or, on the contrary, dropwise.
To obtain an iron phosphate suitable for the needs of the invention, it has been noted that a ratio of 2 times more iron salt than phosphate salt is satisfactory.
Alternatively, the iron phosphate can be prepared using a nebulizer. In this case, the sodium phosphate can be nebulized in a solution of iron chloride or, conversely, the iron chloride in the sodium phosphate.
During the preparation of the vaccine compositions -according to the invention, the iron phosphate can be introduced into the vaccine composition at the very beginning of the formulation. The iron phosphate is then diluted to a certain concentration, and the 5 antigens of interest are then added thereto.
Alternatively, it is possible to add the iron phosphate to a lyophilisate already comprising the portion of the vaccine composition which contains the antigens of interest.
According to the invention, the iron phosphate is present in the vaccine composition in a sufficient amount to exert an adjuvant action.
When it is the only adjuvant used, the dose of vaccine composition administered can comprise between 0.2 and 1.4 mg of iron phosphate.
When it is combined with another adjuvant, the amounts present can be reduced, as a function of the desired adjuvant effect and of the potency of the other adjuvants present.
Local and systemic toxicity tests on rabbits have shown that iron phosphate is as well tolerated as aluminum hydroxide.
The following examples illustrate particular embodiments of the present invention.
Example 1: Preparation of iron phosphate and of iron hydroxide The iron phosphate is prepared by mixing FeC13.6H20 at 0.5 M (supplied by SIGMA under the batch reference 55H 1251) in a solution of Na2HPO4.2H2O at 0.25 M
(supplied by Merck with the batch reference FA004911).
= - 6 -The 2 products are mixed in the following proportions:
1 1 of ultrafiltered water comprising 44.5 g of Na2HPO4.2H20 is combined with a solution of 800 ml of ultrafiltered H2O comprising 108.12 g of FeC13.6H20. The mixing is performed at ambient temperature.
Stirring is performed for 15 minutes by means of a rod-stirrer and then successive centrifugations are carried out with the precipitate being washed with water. After each wash, the presence of chloride ions is detected by assaying the chloride ions with silver nitrate. When there are no longer any chloride ions, i.e. after 10 washes, the precipitate is taken up in water and autoclaved for 1 h at 118 C in order to ensure its sterility.
The solution obtained in this manner is an iron phosphate solution containing 16 g Fe/1.
The iron hydroxide is prepared by mixing 0.5 M iron citrate and 2 M NaOH, at ambient temperature. NaOH is added dropwise to 100 ml of iron citrate until a pH of 8 is obtained. In the same way as for the preparation of the iron phosphate, stirring is performed for 15 minutes and then successive centrifugations are carried out with the precipitate being washed with water, and the chloride ions being assayed with silver nitrate. When chloride ions are no longer detected, the precipitate is taken up in water and autoclaved for 1 h at 118 C in order to be sterile. The solution then obtained is an iron hydroxide solution containing 6.3 g Fe/l.
Example 2: Preparation of the vaccine compositions Using the solutions prepared as indicated above, an aqueous suspension of aluminum hydroxide (supplied by Reheis) comprising 10.8 g of Al/l, and also a preparation of PTP (purified tetanus protein) at a concentration of 330 flocculation or Lf units/ml (i.e.
a protein concentration of 0.9125 g/1), the following compositions are prepared:
= PTP alone: 840 pl H2O + 120 pl 9% NaC1 +
240 PTP at 100 Lf/ml, = PTP and A1OOH : 618 pl H2O + 222 pl A100H at 10.8 g of Al/l + 120 pl 9% NaC1 + 240 PTP at 100 Lf/ml, = PTP and FePO4: 690 pl H2O + 150 pl. FePO4 at 16 g/l + 120 p1 of a 10 times-concentrated PBS
buffer solution (i.e. 95 mM Na2HPO4.2H2O) +
240 PTP at 100 Lf/ml, = PTP and FeOOH: 458 pl H2O + 382 pl FeOOH at 6.3 g of Fe/1 + 120 p1 of a 10 times-concentrated PBS buffer solution + 240 PTP at 100 Lf/ml.
Example 3: Assaying of the anti-tetanus antibodies 4 groups of six 6-week-old female OF1 mice are used.
One of the formulations prepared in example 2 is administered to each group of mice. The administration is performed intramuscularly in the quadriceps under anesthesia, at a rate of 2 injections of 50 pl on days Dl and D22. The amount administered is therefore 2 flocculation or Lf units of PTP and 0.2 mg of mineral material (either aluminum or iron) in the case of the formulations comprising an adjuvant.
On D15, a blood sample of approximately 300 pl is taken from the retro-orbital sinus in each mouse.
On D36, the mice are bled out under anesthesia, by sectioning of the carotid.
The PTP-specific IgGls and IgG2as are assayed, by the ELISA method, on each of the sera corresponding to the bloods collected.
The results obtained are given in figures 1 to 4 and show that the iron phosphate is a good adjuvant; as regards the IgGis, the results obtained are clearly superior to those obtained when the antigen is administered alone, even though they are not quite as good as those obtained with the aluminum hydroxide; as regards the IgG2as, the titers obtained are as high as those obtained with the aluminum hydroxide.
Example 4: Verification of the anti-tetanus activity The anti-tetanus activity of the compositions according to the invention is verified by means of a test consisting in evaluating, in mice, the activity of these compounds with respect to a lethal dose of toxin administered subcutaneously.
The activity of the compositions tested is determined by comparing the dose required to protect 50% of the animals (ED50) against the effects of the toxin, with that of a reference vaccine calibrated in IU/ml.
The formulations tested are obtained by mixing the adjuvant (0.6 mg/dose) with water, 30 Lf of PDT
(diphtheria toxoid) and 10 Lf of PTT (tetanus toxoid), and then adding 20 pg/dose of merthiolate and a saline solution (solution containing 90 g/l of NaC1 and 5 mM
Na2HP04.2H20) .
The vaccine compositions tested comprise either aluminum hydroxide or iron phosphate or iron hydroxide.
The results obtained with each of the adjuvants tested are reported in the table below, and show that iron phosphate is a good adjuvant, clearly better than iron hydroxide under the same conditions:
Adjuvants Tetanus activity (IU/dose) A100H 103 (76-139) FePO4 32 (24-43) FeOOH 8.2 (5.4-12.5)
Claims (8)
1. A vaccine composition comprising at least one vaccine antigen and at least one adjuvant, characterized in that the adjuvant comprises iron phosphate.
2. The vaccine composition of claim 1, characterized in that the iron phosphate is present in the form of a suspension of particles, the size of which is between 0.01 µm and 300 µm.
3. The vaccine composition of claim 2, characterized in that the particles have a size between 1 and 40 µm.
4. The vaccine composition as claimed in claim 2 or 3, characterized in that the particles have a size centered around a value of 7 µm.
5. The vaccine composition as claimed in any one of claims 1 to 4, characterized in that the iron phosphate is prepared from a solution of iron salt and of phosphate salt.
6. The vaccine composition as claimed in any one of claims 1 to 5, characterized in that it comprises at least a tetanus antigen.
7 The vaccine composition as claimed in any one of claims 1 to 6, characterized in that it comprises at least a diphtheria antigen.
8. The vaccine composition as claimed in any one of claims 1 to 7, characterized in that it comprises at least one poliomyelitis antigen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR03/05876 | 2003-05-16 | ||
| FR0305876A FR2854803B1 (en) | 2003-05-16 | 2003-05-16 | VACCINE COMPOSITION COMPRISING IRON PHOSPHATE AS VACCINE. |
| PCT/FR2004/001175 WO2004103408A2 (en) | 2003-05-16 | 2004-05-14 | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2525615A1 CA2525615A1 (en) | 2004-12-02 |
| CA2525615C true CA2525615C (en) | 2012-03-13 |
Family
ID=33306396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2525615A Expired - Fee Related CA2525615C (en) | 2003-05-16 | 2004-05-14 | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1628683B1 (en) |
| JP (1) | JP4711964B2 (en) |
| CN (1) | CN100384476C (en) |
| AT (1) | ATE430582T1 (en) |
| CA (1) | CA2525615C (en) |
| DE (1) | DE602004020985D1 (en) |
| FR (1) | FR2854803B1 (en) |
| WO (1) | WO2004103408A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571925A (en) * | 2018-03-08 | 2019-09-18 | Univ Antwerpen | Iron-based vaccine adjuvants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE565793A (en) * | 1957-03-19 | 1900-01-01 | ||
| DE3834729A1 (en) * | 1988-10-12 | 1990-04-19 | Behringwerke Ag | USE OF ZINC OR IRON HYDROXIDE FOR ADJUVATING ANTIGEN SOLUTIONS AND ANY ADJUSTED ANTIGEN SOLUTIONS THEREFOR |
| DE19511276C2 (en) * | 1995-03-27 | 1999-02-18 | Immuno Ag | Adjuvant based on colloidal iron compounds |
| DE69935606T9 (en) * | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | ADJUVANCE SYSTEMS AND VACCINE |
| GB0025058D0 (en) * | 2000-10-12 | 2000-11-29 | Smithkline Beecham Biolog | Composition |
| RU2323002C2 (en) * | 2001-07-26 | 2008-04-27 | Чирон Срл. | Vaccines comprising aluminum adjuvants and histidine |
-
2003
- 2003-05-16 FR FR0305876A patent/FR2854803B1/en not_active Expired - Fee Related
-
2004
- 2004-05-14 DE DE602004020985T patent/DE602004020985D1/en not_active Expired - Lifetime
- 2004-05-14 JP JP2006530351A patent/JP4711964B2/en not_active Expired - Fee Related
- 2004-05-14 WO PCT/FR2004/001175 patent/WO2004103408A2/en active Application Filing
- 2004-05-14 AT AT04742725T patent/ATE430582T1/en not_active IP Right Cessation
- 2004-05-14 CA CA2525615A patent/CA2525615C/en not_active Expired - Fee Related
- 2004-05-14 CN CNB2004800133652A patent/CN100384476C/en not_active Expired - Fee Related
- 2004-05-14 EP EP04742725A patent/EP1628683B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN100384476C (en) | 2008-04-30 |
| ATE430582T1 (en) | 2009-05-15 |
| FR2854803A1 (en) | 2004-11-19 |
| WO2004103408A2 (en) | 2004-12-02 |
| JP4711964B2 (en) | 2011-06-29 |
| WO2004103408A3 (en) | 2005-03-17 |
| EP1628683B1 (en) | 2009-05-06 |
| DE602004020985D1 (en) | 2009-06-18 |
| CA2525615A1 (en) | 2004-12-02 |
| CN1791432A (en) | 2006-06-21 |
| JP2006528958A (en) | 2006-12-28 |
| EP1628683A2 (en) | 2006-03-01 |
| FR2854803B1 (en) | 2005-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Advances in aluminum hydroxide-based adjuvant research and its mechanism | |
| RU2325184C2 (en) | Improvement of bacteria outer membrane vesicle | |
| JP5075317B2 (en) | Capsular polysaccharide solubilization and combination vaccine | |
| JPH07504683A (en) | Use of GM-CSF as a vaccine adjuvant | |
| JPH07505372A (en) | Hepatitis vaccine containing 3-O-deacylated monophosphoryl lipid A | |
| SK283565B6 (en) | Multivalent DTP-polio vaccines | |
| JP4947506B2 (en) | A novel non-antigenic mucosal adjuvant formulation that modulates the effects of substances including vaccine antigens by contacting the mucosal surface | |
| JP6796146B2 (en) | Aluminum hydroxide gel-sodium chloride composite immunological adjuvant, its preparation method and its use | |
| JP2010105968A (en) | Mucosal vaccine using cationic nanogel | |
| JP2000103745A (en) | Prescribed substance | |
| EP0789590B1 (en) | Chitosan induced immunopotentiation | |
| SA519401232B1 (en) | A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof | |
| EP0734725B1 (en) | Adjuvants containing colloidal iron compounds | |
| JP2756321B2 (en) | Antigen solution containing zinc hydroxide or iron hydroxide as adjuvant | |
| JP2004189751A (en) | Acellular pertussis vaccines and methods of preparation thereof | |
| US20220211859A1 (en) | Conjugate production | |
| CA2525615C (en) | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine | |
| JPH07300427A (en) | Combination infantile vaccine enhanced in immunogenicity of each vaccine ingredient | |
| CN112996538A (en) | Immunogenic compositions | |
| JP4530317B2 (en) | Vaccine formulation containing attenuated toxin | |
| US6927235B2 (en) | Vaccine composition comprising iron phosphate as vaccine adjuvant | |
| WO2018162428A1 (en) | Pentavalent streptococcus suis vaccine composition | |
| JP4331798B2 (en) | Allergen prescription | |
| JPH0236129A (en) | Agent forpromoting effect of vaccine | |
| US20240173394A1 (en) | Immunogenic fusion protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170515 |